Betta Pharmaceuticals
VC Fund
Hangzhou, China
Betta Pharmaceuticals is a state-level hi-tech pharmaceutical enterprise, established by a team of returned PhD holders, which focuses on R&D of innovative medicines based on independent IPR, integrating R&D, manufacturing and marketing. Betta Pharmaceuticals has been dedicating to the R&D and manufacturing of National Class A newmedicines with independent IPR. Betta Pharmaceuticals is a state-level hi-tech pharmaceutical enterprise, established by a team of returned PhD holders in 2003, which focuses on R&D of innovative medicines based on independent IPR, integrating R&D, manufacturing and marketing. Betta Pharmaceuticals has been dedicating to diseases severely influencing human health, e.g. malignant tumors, diabetes, and cardio-cerebrovascular disease. Its headquarters is located at Yuhang Economic and Technological Development Zone, Hangzhou City, with a pharmaceutical R&D center established in Beijing and Hangzhou respectively. At present, it boasts a team of nearly 1,000 employees, in which there are dozens of returned PhD holders with five of them included in The Recruitment Program of Global Experts of China. On Nov. 7th, 2016, Betta Pharmaceuticals was successfully listed in GEM of Shenzhen Stock Exchange. Betta has over 20 new drug development projects currently, among which its flagship product, Icotinib Hydrochloride (Conmana), has created several records: in Jul. 2012, it was involved in The International Annual Report on New Drug Research and Development, as the first targeted anti-cancer drug made in China; in Aug. 2013, Lancet Oncol, a world leading medical magazine, published a full text of China’s clinical research achievement of innovative drugs for the first time and commended that “Icotinib Hydrochloride has created the new era of China’s R&D of anti-cancer drugs”, according to the Editor’s Note; the compound and crystal form patents of Icotinib Hydrochloride won the Golden Prize of China Patent Award in 2012 and 2014 respectively; the R&D and industrialized achievement of Icotinib Hydrochloride won the First Prize of 2015 National Prize for Progress in Science and Technology, as the first time that this award was won by China’s chemical pharmaceutical industry and Zhejiang enterprise; in 2016, Icotinib Hydrochloride (Conmana) won the highest award of China’s industrial area, China Grand Award for Industry. The Company possesses over 100 authorized patents with other hundreds of patents applied in process; sets 4 technical standards, in which the standard for Icotinib Hydrochloride crude drugs and tablets has turned into national standard; won national special award of Key Formulation of New Drugs for several times and was involved in MOST National High-tech R&D Program (863 Program), China Torch Program and National Strategic Innovative Product. Independent R&D, strategic cooperation and marketing are the three driving factors promoting the better and faster development of Betta, laying a solid foundation for the realization of its strategic vision of “turning into a transnational pharmaceutical enterprise headquartered in China”. Innovation is of no bounds. Betta Pharmaceuticals will continue to carry forward its development concept as pioneering innovation to the benefit of the public, devote itself to innovation for the public and technology development benefiting the public by means of development of new medicines, to provide Chinese residents with more affordable medicines of good quality.
- Total investments:
- 9
- Last investment:
- Lead investor:
- 67%
Last updated:
For AI agents: llms.txt
Industries Betta Pharmaceuticals invests in
Stages Betta Pharmaceuticals invests in
Countries Betta Pharmaceuticals invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Lieming Ding
|
|||
Investment Focus
Industry
- Health Care 7 (78%)
- Biotechnology 5 (56%)
- Medical 4 (44%)
- Pharmaceutical 3 (33%)
- Health Diagnostics 3 (33%)
Stage
- Angel 3 (33%)
- Series A 3 (33%)
- Private Equity 1 (11%)
- Post-IPO Equity 1 (11%)
- Secondary Market 1 (11%)
Country
- China 6 (67%)
- United States 3 (33%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Lieming Ding
Founder, Chairman & Chief Executive Officer
|
Founder, Chairman & Chief Executive Officer | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
Zhixing Pharmaceutical
|
Zhixing Pharmaceutical is a specialized pharmaceutical company dedicated to the research, development, and large-scale production of high-end inhaled formulations, leveraging advanced drug delivery technologies, rigorous quality systems, and innovative R&D capabilities to provide safe, effective, and high-quality respiratory therapies. | $7.2M / Secondary Market / Jan 09, 2026 | |
Reprogenix
|
Reprogenix is a groundbreaking medical technology firm that began with stem cell therapy for diabetes and is dedicated to expanding the use of cell therapy in a wide range of disease areas. | $14.1M / Series A / Nov 04, 2024 | |
Gaowei Medicine
|
Gaowei Medicine is a drug discovery platform for developing new drugs for key intractable diseases such as cancer and neurological diseases. | Angel / Jul 20, 2023 | |
C4 Therapeutics
|
C4 is building on the knowledge with synthetic chemical compounds which it calls Degronimids. These compounds can be engineered and linked together to bind with many molecular targets that today’s drugs can’t bind with, Cohen said. The key insight, he said, is that the scientific founders have discovered a way to bind with select disease-causingproteins, and flag them as cellular trash, so that the ordinary proteasome garbage disposal system can get rid of them. Selecting the precise disease-related proteins to send to the trash is obviously critical, because any drug like this could cause serious side effects if it sent healthy proteins involved in normal cell processes to the trash.C4 Therapeutics is developing a new class of targeted protein degradation (TPD) therapeutics for the treatment of a broad range of diseases. Our Degronimid™ platform incorporates highly selective small molecule binders to target disease-causing proteins and facilitate their rapid destruction and clearance from the cell through the natural ubiquitin/proteasome system (UPS). Because of this distinctive mechanism, Degronimids are capable of hitting many more targets, including those previously thought to be undruggable, while reducing the potential for drug resistance. The broad applicability of Degronimids, and our chemical biology platform designed for accelerated validation, have the potential to make an unprecedented impact across many diseases through multiple industry collaborations as well as proprietary programs.The Company has received an exclusive worldwide license to the Degronimid platform and related IP from Dana-Farber. | $25M / Post-IPO Equity / May 30, 2023 | |
E-nitiate Biopharmaceuticals
|
E-nitiate Biopharmaceuticals is committed to the development of innovative drugs for autoimmune diseases, through independent research and development, and strategic collaborations, to address unmet medical needs and to improve the quality of human life. | $3M / Angel / Aug 31, 2022 | |
Centrymed
|
Centrymed focuses on the field of tumor treatment, and its self-developed dual-antibody platform. The company's independent intellectual property rights have solved the problems of drug drugability and toxic and side effects of antibody drugs. | Series A / Feb 09, 2022 | |
Capio Biosciences
|
Capio Biosciences is a biotech company focused on delivering high-value oncology diagnostics that can help inform patient care decisions and improve outcomes. Capio Biosciences is developing an advanced platform called CapioCyte™ for the capture of circulating tumor cells (CTCs) from whole blood. By utilizing a combination of biomimetic cellrolling and dendrimer-mediated multivalent cell capture, CapioCyte delivers significantly greater capture sensitivity than other platforms currently available. It is also able to provide enriched CTCs for post capture molecular analysis such as FISH, RNA-Seq and NGS. CapioCyte is therefore an excellent tool for today’s cancer research needs, and potentially for clinical patient management in the future. | $2.9M / Series A / Jan 05, 2017 | |
Hangzhou DAC Biotech Co., Ltd
|
Hangzhou DAC Biotech Co., Ltd focuses on developing conjugate of monoclonal antibody and small molecular cytotoxic drugs. | $5.7M / Angel / Nov 27, 2015 | |
Xcovery
|
Founded in 2006 and headquartered in West Palm Beach, Florida, Xcovery is comprised of an experienced team that is dedicated to advancing next generation targeted therapeutics as promising new treatments to improve the lives of cancer patients. Xcovery’s mission is to develop low toxicity molecular targeted oral drugs which will allow continuoustherapy and will not require dosing “holidays”. Low toxicity will allow a greater “therapeutic window” and the ability to more effectively treat multiple cancers with higher potency. Low toxicity will also allow our drugs to better be used in combination therapy where other, current therapies, are too toxic to be effective.Our Team Xcovery’s CEO, Sheridan Snyder, is a veteran entrepreneur who began his biotech career in 1981 when he founded Genzyme, followed by Biotage, Upstate Biotechnology and now Xcovery and Tyrogenex. Mr. Snyder has funded Xcovery’s first 5 years of development, through his personal investment vehicle, BioCatalyst International, Inc. This is consistent with his “formula” for developing more than 14 start-ups over a 40 year period, all of which are operating successfully today.Xcovery’s Chief Scientific Officer, Dr. Chris Liang, served as Director, Medicinal Chemistry at SUGEN (acquired by Pfizer in 2003) where he developed Sutent®, an FDA approved VEGFR/PDGFR angiogenesis inhibitor for the treatment of kidney cancer and second-line gastrointestinal cancer in Gleevec-resistant patients. The result of his knowledge, extensive experience and a unique set of medicinal chemistry design tools have enabled Xcovery to create a broad portfolio of kinase inhibitors.Xcovery’s Vice President, Oncology, Dr. Jay Gibbons, brings more than 25 years of oncology research and management experience to the team with a strong emphasis on translational medicine. During his previous role as AVP, Oncology Research at Wyeth, he was instrumental in filing eight IND’s and the NDA for Torisel® (temsirolimus), currently approved for the treatment of renal cell carcinoma. | $20M / Private Equity / Oct 29, 2014 |
Co-Investors
Addor Capital
1 deal together
China Venture Capital
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Betta Pharmaceuticals invest in?
Betta Pharmaceuticals invests primarily in Health Care, Biotechnology and Medical startups, most often at Angel and Series A stage. Most of the 9 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Betta Pharmaceuticals?
Public channels for Betta Pharmaceuticals include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Betta Pharmaceuticals?
The team at Betta Pharmaceuticals includes Lieming Ding (Founder, Chairman & Chief Executive Officer). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
